290 related articles for article (PubMed ID: 33826709)
41. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL
Clin J Am Soc Nephrol; 2023 Jun; 18(6):748-758. PubMed ID: 36999981
[TBL] [Abstract][Full Text] [Related]
42. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
43. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
44. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Liao J; Kang A; Xia C; Young T; Di Tanna GL; Arnott C; Pollock C; Krishnan AV; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B
Diabetes Metab; 2022 Jul; 48(4):101331. PubMed ID: 35172198
[TBL] [Abstract][Full Text] [Related]
45. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Jackson K; Moseley KF
Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
[TBL] [Abstract][Full Text] [Related]
46. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Sen T; Koshino A; Neal B; Bijlsma MJ; Arnott C; Li J; Hansen MK; Ix JH; Heerspink HJL
Diabetes Obes Metab; 2022 Oct; 24(10):1950-1956. PubMed ID: 35635326
[TBL] [Abstract][Full Text] [Related]
48. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
49. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
50. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL
J Am Heart Assoc; 2021 Dec; 10(23):e021661. PubMed ID: 34854308
[TBL] [Abstract][Full Text] [Related]
51. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Ye N; Jardine MJ; Oshima M; Hockham C; Heerspink HJL; Agarwal R; Bakris G; Schutte AE; Arnott C; Chang TI; Górriz JL; Cannon CP; Charytan DM; de Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Wheeler DC; Luca Di Tanna G; Cheng H; Perkovic V; Neuen BL
Circulation; 2021 May; 143(18):1735-1749. PubMed ID: 33554616
[TBL] [Abstract][Full Text] [Related]
52. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR;
Diabetes Obes Metab; 2017 Jul; 19(7):926-935. PubMed ID: 28244644
[TBL] [Abstract][Full Text] [Related]
53. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
54. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
55. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
56. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
57. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Sen T; Ju W; Nair V; Ladd P; Menon R; Otto EA; Pyle L; Vigers T; Nelson RG; Arnott C; Neal B; Hansen MK; Kretzler M; Bjornstad P; Heerspink HJL
Kidney Int; 2023 Oct; 104(4):828-839. PubMed ID: 37543256
[TBL] [Abstract][Full Text] [Related]
58. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
59. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):903-914. PubMed ID: 33065060
[TBL] [Abstract][Full Text] [Related]
60. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.
Li J; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B
Lancet Rheumatol; 2019 Dec; 1(4):e220-e228. PubMed ID: 38229378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
